The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury

Aims: During ischemia/reperfusion (I/R), ribosomal S6 kinase (RSK) activates Na+/H+ exchanger 1 (NHE1) by phosphorylating NHE1 at serine 703 (pS703-NHE1), which promotes cardiomyocyte death and injury. Pharmacologic inhibition of NHE1 effectively protects animal hearts from I/R. However, clinical trials using NHE1 inhibitors failed to show benefit in patients with acute myocardial infarction (MI). One possible explanation is those inhibitors block both agonist-stimulated activity (increasing I/R injury) and basal NHE1 activity (necessary for cell survival). We previously showed that dominant-negative RSK (DN-RSK) selectively blocked agonist-stimulated NHE1 activity. Therefore, we hypothesized that a novel RSK inhibitor (BIX02565) would blunt agonist-stimulated NHE1 and protect hearts from I/R. Methods and Results: Serum/angiotensin II-stimulated pS703-NHE1 was significantly decreased by BIX02565 in cultured cells. Intracellular pH recovery assay showed that BIX02565 selectively inhibited serum-stimulated NHE1 activity. Ischemia/reperfusion decreased left ventricular–developed pressure (LVDP; inhibited) to 8.7% of the basal level in non-transgenic littermate control (NLC) mouse hearts, which was significantly improved (44.6%) by BIX02565. Similar protection was observed in vehicle-treated, cardiac-specific DN-RSK-Tg mice (43%). No additional protective effect was seen in BIX02565-treated DN-RSK-Tg hearts. BIX02565 also improved LVDP in cardiac-specific wild-type (WT)-RSK-Tg mouse hearts (7.4%-40.9%, P < .01). Finally, Western Blotting results confirmed DN-RSK and BIX02565 significantly decreased I/R-induced pS703-NHE1. Conclusion: The RSK plays a crucial role in I/R-induced activation of NHE1 and cardiac injury. The RSK inhibition may provide an alternative target for patients with MI.

[1]  M. KirraneThomas.  Indole RSK Inhibitors. Part 2. Optimization of Cell Potency and Kinase Selectivity. , 2012 .

[2]  J. Madwed,et al.  Mitigation of Off-Target Adrenergic Binding and Effects on Cardiovascular Function in the Discovery of Novel Ribosomal S6 Kinase 2 Inhibitors , 2012, Journal of Pharmacology and Experimental Therapeutics.

[3]  Chen Yan,et al.  p90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: a pathogenic mechanism for ischemia-reperfusion injury. , 2011, Journal of molecular and cellular cardiology.

[4]  Y. Tintut,et al.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification. , 2011, Circulation research.

[5]  L. Kirshenbaum,et al.  Multiple facets of NF-κB in the heart: to be or not to NF-κB. , 2011, Circulation Research.

[6]  E. Cingolani,et al.  Silencing of cardiac mitochondrial NHE1 prevents mitochondrial permeability transition pore opening. , 2011, American journal of physiology. Heart and circulatory physiology.

[7]  S. Ghosh,et al.  NF-κB, inflammation, and metabolic disease. , 2011, Cell metabolism.

[8]  Z. Gąsior,et al.  Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB): a new potential therapeutic target in atherosclerosis? , 2010, Pharmacological reports : PR.

[9]  P. Karki,et al.  Sustained intracellular acidosis activates the myocardial Na(+)/H(+) exchanger independent of amino acid Ser(703) and p90(rsk). , 2010, Biochimica et biophysica acta.

[10]  P. Karki,et al.  Phenylephrine and sustained acidosis activate the neonatal rat cardiomyocyte Na+/H+ exchanger through phosphorylation of amino acids Ser770 and Ser771. , 2009, American journal of physiology. Heart and circulatory physiology.

[11]  R. Jabr,et al.  Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress? , 2009, Journal of molecular and cellular cardiology.

[12]  D. Allen,et al.  Why did the NHE inhibitor clinical trials fail? , 2009, Journal of molecular and cellular cardiology.

[13]  H. Cingolani,et al.  Na + / H + exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action , 2008 .

[14]  J. Blenis,et al.  The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.

[15]  T. Nguyen.  Targeting RSK: an overview of small molecule inhibitors. , 2008, Anti-cancer agents in medicinal chemistry.

[16]  M. Avkiran,et al.  Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach? , 2008, Current opinion in pharmacology.

[17]  E. Murphy,et al.  Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. , 2008, Physiological reviews.

[18]  G. Buckberg,et al.  Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. , 2008, The Annals of thoracic surgery.

[19]  L. Fliegel,et al.  Overexpression of the Na+/H+ exchanger and ischemia-reperfusion injury in the myocardium. , 2007, American journal of physiology. Heart and circulatory physiology.

[20]  L. Fliegel,et al.  Mitogen-activated Protein Kinase-dependent Activation of the Na+/H+ Exchanger Is Mediated through Phosphorylation of Amino Acids Ser770 and Ser771* , 2007, Journal of Biological Chemistry.

[21]  Michael S. Cohen,et al.  Evidence for Direct Regulation of Myocardial Na+/H+ Exchanger Isoform 1 Phosphorylation and Activity by 90-kDa Ribosomal S6 Kinase (RSK): Effects of the Novel and Specific RSK Inhibitor fmk on Responses to α1-Adrenergic Stimulation , 2007, Molecular Pharmacology.

[22]  J. Abe,et al.  Inhibiting p90 Ribosomal S6 Kinase Prevents Na+-H+ Exchanger–Mediated Cardiac Ischemia-Reperfusion Injury , 2006, Circulation.

[23]  Y. Takeishi,et al.  Role of p90 Ribosomal S6 Kinase–Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium , 2006, Circulation.

[24]  F. Di Sole,et al.  Na+/H+ exchangers: physiology and link to hypertension and organ ischemia , 2005, Current opinion in nephrology and hypertension.

[25]  M. Karmazyn,et al.  The Na(+)/H(+) exchanger: a target for cardiac therapeutic intervention. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[26]  Michael S. Cohen,et al.  Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.

[27]  Timothy M. Errington,et al.  Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. , 2005, Cancer research.

[28]  M. Avkiran,et al.  Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass , 2004, British journal of pharmacology.

[29]  G. Valen.  Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure , 2003, Basic Research in Cardiology.

[30]  M. Ashraf,et al.  Mice With a Null Mutation in the NHE1 Na+-H+ Exchanger Are Resistant to Cardiac Ischemia-Reperfusion Injury , 2003, Circulation research.

[31]  H. Cingolani,et al.  NHE-1 and NHE-6 activities: ischemic and reperfusion injury. , 2003, Circulation research.

[32]  J. Blenis,et al.  Phosphorylation of p90 Ribosomal S6 Kinase (RSK) Regulates Extracellular Signal-Regulated Kinase Docking and RSK Activity , 2003, Molecular and Cellular Biology.

[33]  T. Sturgill,et al.  Characterization of the p90 Ribosomal S6 Kinase 2 Carboxyl-terminal Domain as a Protein Kinase* , 2002, The Journal of Biological Chemistry.

[34]  P. Brookes,et al.  Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. , 2002, Free radical biology & medicine.

[35]  M. Marber,et al.  Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. , 2002, Journal of the American College of Cardiology.

[36]  H. Suryapranata,et al.  The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. , 2001, Journal of the American College of Cardiology.

[37]  J. Abe,et al.  14-3-3 Binding to Na+/H+ Exchanger Isoform-1 Is Associated with Serum-dependent Activation of Na+/H+ Exchange* , 2001, The Journal of Biological Chemistry.

[38]  R. J. Hill,et al.  Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. , 2001, Bioorganic & medicinal chemistry letters.

[39]  H. White,et al.  Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations: Main Results of the GUARDIAN Trial , 2000, Circulation.

[40]  S. Gammeltoft,et al.  A phosphoserine‐regulated docking site in the protein kinase RSK2 that recruits and activates PDK1 , 2000, The EMBO journal.

[41]  E. Krebs,et al.  p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. , 1999, The Journal of biological chemistry.

[42]  M. Karmazyn.  The Role of the Myocardial Sodium‐Hydrogen Exchanger in Mediating Ischemic and Reperfusion Injury: From Amiloride to Cariporide a , 1999, Annals of the New York Academy of Sciences.

[43]  S. Gammeltoft,et al.  Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction , 1999, Molecular and Cellular Endocrinology.

[44]  M. Avkiran,et al.  Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. , 1999, The American journal of cardiology.

[45]  W. Frishman,et al.  Sodium Ion/Hydrogen Ion Exchange Inhibition: A New Pharmacologic Approach to Myocardial Ischemia and Reperfusion Injury , 1998, Journal of clinical pharmacology.

[46]  M. Karmazyn,et al.  A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). , 1997, Journal of molecular and cellular cardiology.

[47]  W. Greene,et al.  The 90-kDa Ribosomal S6 Kinase (pp90rsk) Phosphorylates the N-terminal Regulatory Domain of IκBα and Stimulates Its Degradation in Vitro * , 1997, The Journal of Biological Chemistry.

[48]  J. Abe,et al.  Angiotensin II stimulates p90rsk in vascular smooth muscle cells. A potential Na(+)-H+ exchanger kinase. , 1997, Circulation research.

[49]  W. Linz,et al.  Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. , 1995, Cardiovascular research.

[50]  R. Alexander,et al.  Vascular smooth muscle Na+-H+ exchanger kinetics and its activation by angiotensin II. , 1988, The American journal of physiology.

[51]  J. Madwed,et al.  Indole RSK inhibitors. Part 1: discovery and initial SAR. , 2012, Bioorganic & medicinal chemistry letters.

[52]  G. Lopaschuk,et al.  Elevated levels of activated NHE1 protect the myocardium and improve metabolism following ischemia/reperfusion injury. , 2011, Journal of molecular and cellular cardiology.

[53]  P. Cohen,et al.  BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. , 2007, The Biochemical journal.

[54]  D. Kintner,et al.  Inhibition of Na+/H+ exchanger isoform 1 attenuates mitochondrial cytochrome C release in cortical neurons following in vitro ischemia. , 2006, Acta neurochirurgica. Supplement.

[55]  M. Krop.  “ Role of p 90 Ribosomal S 6 Kinase-Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium ” , 2006 .

[56]  G. Heijne,et al.  Structural Bioinformatics-Based Design of Selective , Irreversible Kinase Inhibitors , 2005 .

[57]  Y. Takeishi,et al.  Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. , 2002, Cardiovascular research.

[58]  W. Greene,et al.  The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. , 1997, The Journal of biological chemistry.